Skip to main content

Table 3. 2DE structural and functional parameters at 2 weeks

From: The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

 

Level

Parameter

Group

Control

Empagliflozin

Apical level

Systolic

LVESA [mm2]

47.5 ± 4.3***

54.4 ± 5.1***

LVIDs [mm]

7.1 ± 0.4***

7.9 ± 0.5***

Diastolic

LVEDA [mm2]

69.3 ± 4.4***

74.3 ± 5.3***

LVIDd [mm]

8.8 ± 0.4***

9.3 ± 0.4***

Function

FS [%]

19.1 ± 3.3**

15.1 ± 4.0**

FAC [%]

33.6 ± 3.0***

27.2 ± 3.5***

EF [%]

42.9 ± 5.4**

34.9 ± 6.4**

Papillary muscles level

Systolic

LVESA [mm2]

47.1 ± 3.4***

52.4 ± 4.0***

LVIDs [mm]

7.8 ± 0.4***

7.5 ± 0.5***

Diastolic

LVEDA [mm2]

78.4 ± 3.8***

80.2 ± 4.5***

LVIDd [mm]

9.5 ± 0.2***

9.3 ± 0.3*** #

Function

FS [%]

17.8 ± 2.7***

20.1 ± 3.2**

FAC [%]

39.3 ± 2.9***

35.7 ± 3.4**

EF [%]

40.2 ± 4.6***

45.4 ± 5.4**

  1. Abbs. as in Table 2. ** P < 0.01 vs. baseline and *** P < 0.001 vs. baseline, # P < 0.05 vs. damage group